Friday, Aug 28, 2026 The claims desk. Receipts included. POWERED BY LENZ ↗
IsThis

Semaglutide has documented ocular risks, including rare vision-threatening NAION.

The Claim

GLP-1 receptor agonist treatment has numerous side effects, including adverse effects on eyesight.

Verified by Lenz ·

The Short Version

GLP-1 treatment can have many side effects, and official safety information documents potential eye complications. The clearest evidence concerns semaglutide, including diabetic-retinopathy complications and very rare NAION, which can cause vision loss. Evidence does not establish the same ocular risk for every GLP-1 drug, and several broad analyses have found no significant overall increase in eye disorders.

Caveats

  • The strongest eye-risk evidence applies to semaglutide, not uniformly to every GLP-1 receptor agonist.
  • NAION is classified as a very rare adverse effect, reported in up to 1 in 10,000 semaglutide users.
  • Observational safety signals do not prove causation, and randomized-trial meta-analyses have produced mixed or null findings.

The Receipts

  1. GLP-1RA and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy in Patients with Type 2 Diabetes: A Population-based Study - PMC

    pmc.ncbi.nlm.nih.gov

  2. Label: WEGOVY- semaglutide injection, solution

    dailymed.nlm.nih.gov

  3. RYBELSUS (Novo Nordisk): FDA Package Insert, Page 2

    medlibrary.org

  4. DRUG SAFETY UPDATE (DSU)

    assets.publishing.service.gov.uk

  5. MHRA updates guidance for semaglutide prescribers and patients - GOV.UK

    gov.uk

  6. Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) – a systematic review and meta-analysis - PMC

    pmc.ncbi.nlm.nih.gov

  7. Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data | BMC Medicine | Springer Nature Link

    link.springer.com

  8. HIGHLIGHTS OF PRESCRIBING INFORMATION

    dailymed.nlm.nih.gov

  9. Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis

    pubmed.ncbi.nlm.nih.gov

  10. MHRA SAFETY ROUNDUP

    assets.publishing.service.gov.uk

+ 40 more sources — see the full list on Lenz

Filed Under

GLP-1 receptor agonists

More Fact Checks